Gene Therapy in Neurodegenerative Disorders

Dr. Vahid Mansouri's passion for continuous learning and innovative solutions led him from an MD degree at Isfahan University of Medical Sciences, where he was honored as the Outstanding Medical Student in Iran in 2017, to a focus on translational science. Actively involved in biomedical and clinical research, particularly in pediatrics, Dr. Mansouri has authored five first-authored papers. He pursued post-doctoral studies at Tehran University of Medical Sciences' gene therapy research center, gaining diverse skills in wet-lab, dry-lab, animal, and clinical trials. Dr. Mansouri has contributed to pioneering gene therapy projects in Iran, including treatments for X-linked retinitis pigmentosa and spinal muscular atrophy, and developed a clinical trial protocol for CD19 CAR-T cells. Outside of his professional endeavors, he is a national medalist in swimming and water polo, and enjoys trekking, camping, and mountain climbing, which bring balance and vitality to his life. Dr. Maryam Bemanalizadeh is a distinguished medical professional with a Doctorate of Medicine (MD) from Isfahan University of Medical Sciences and a Master of Business Administration (MBA) in Health from Shahid Beheshti University of Medical Sciences. Renowned for her research in neurodegenerative and neurodevelopmental disorders, gene therapy, and neuroscience, she has published extensively in high-impact journals. Dr. Bemanalizadeh's work includes pioneering gene therapy projects and developing clinical trial protocols. As a Research Associate at Tehran University of Medical Sciences and a Senior Researcher at Children's Medical Center, she leads innovative studies on spinal muscular atrophy and Alzheimer's disease. Her contributions to the field are complemented by her role as a mentor at NeuroTRACT Association. Outside of her professional endeavors, Dr. Bemanalizadeh enjoys hiking, camping, traveling, and cooking. She continues to inspire through her dedication to advancing medical science and improving patient care.

• 1. Gene Delivery Modalities for Neurodegenerative Disorders2. Current Advances and Challenges Associated with CNS-targeted Gene Delivery Overview of Gene therapy in Neurodegenerative Disorders3. Gene Therapy in Spinal Muscular Atrophy (SMA)4. Gene Therapy in Amyotrophic Lateral Sclerosis (ALS)5. Gene Therapy in Duchenne Muscular Dystrophy (DMD)6. Gene Therapy in Neuronal Ceroid Lipofuscinosis (NCL)7. Gene Therapy in Mucopolysaccharidoses (MPSs)8. Gene Therapy in Giant Axonal Neuropathy (GAN)9. Gene Therapy in Limb-Girdle Muscular Dystrophy (LGMD)10. Gene Therapy in Pompe Disease11. Gene Therapy in Huntington’s Disease (HD)12. Gene Therapy in Spinocerebellar Ataxia (SCA)13. Gene Therapy in Alzheimer’s Disease (AD)14. Gene Therapy in Parkinson’s Disease (PD)15. Gene Therapy in Facioscapulohumeral Muscular Dystrophy (FSHD)